Han Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Han Li has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Adam Godzik
Division of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, CA 92521, USA
1 shared publication - Greg Ver Steeg
Stevens Neuroimaging and Informatics Institute University of California Riverside CA USA
1 shared publication - Xinru Qiu
Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, CA, United States
1 shared publication
Latest Publications
- Open Access
- 12 March 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (3) , 339
Advances in AI for Protein Structure Prediction: Implications for Cancer Drug Discovery and Development
Recent advancements in AI-driven technologies, particularly in protein structure prediction, are significantly reshaping the landscape of drug discovery and development. This review focuses on the question of how these technological breakthroughs, exemplified by AlphaFold2, are revolutionizing our understanding of protein structure and function changes underlying cancer and improve our approaches to counter them. By enhancing the precision and speed at which drug targets are identified and drug candidates can be designed and optimized, these technologies are streamlining the entire drug development process. We explore the use of AlphaFold2 in cancer drug development, scrutinizing its efficacy, limitations, and potential challenges. We also compare AlphaFold2 with other algorithms like ESMFold, explaining the diverse methodologies employed in this field and the practical effects of these differences for the application of specific algorithms. Additionally, we discuss the broader applications of these technologies, including the prediction of protein complex structures and the generative AI-driven design of novel proteins.
- 12 March 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (3) , 339
Open AccessAdvances in AI for Protein Structure Prediction: Implications for Cancer Drug Discovery and Development
Recent advancements in AI-driven technologies, particularly in protein structure prediction, are significantly reshaping the landscape of drug discovery and development. This review focuses on the question of how these technological breakthroughs, exemplified by AlphaFold2, are revolutionizing our understanding of protein structure and function changes underlying cancer and improve our approaches to counter them. By enhancing the precision and speed at which drug targets are identified and drug candidates can be designed and optimized, these technologies are streamlining the entire drug development process. We explore the use of AlphaFold2 in cancer drug development, scrutinizing its efficacy, limitations, and potential challenges. We also compare AlphaFold2 with other algorithms like ESMFold, explaining the diverse methodologies employed in this field and the practical effects of these differences for the application of specific algorithms. Additionally, we discuss the broader applications of these technologies, including the prediction of protein complex structures and the generative AI-driven design of novel proteins.